Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2019-10-21 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU
Regulatory Filings
2019-10-21 English
Farxiga approved in the US to reduce the risk of
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content details a specific regulatory event: the US FDA approval of the drug Farxiga for a specific indication. This type of material—a press release announcing a significant corporate event (drug approval) distributed through an official regulatory channel—is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it were tied to financial results. Since this is a specific product/regulatory milestone announcement and not a comprehensive financial report (like 10-K or IR) or a management discussion (MDA), and it is explicitly distributed via RNS, the most appropriate general classification for a non-standard announcement is RNS. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR).
2019-10-21 English
TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT
Regulatory Filings
2019-10-17 English
Trastuzumab deruxtecan granted FDA Priority Review
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 1963Q' and is dated '17 October 2019'. It announces regulatory news regarding the FDA granting Priority Review for a drug application (BLA) for Trastuzumab deruxtecan. The text concludes with a statement: 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit mention of RNS strongly indicate a general regulatory announcement disseminated via the RNS system. Since the content is a specific regulatory update that doesn't fit perfectly into the other specialized categories (like 10-K, ER, or DIV), the most appropriate classification is the general Regulatory Filings fallback category (RNS). The document length is substantial (over 10,000 characters), so it is not a simple RPA.
2019-10-17 English
FORM 4 SUBMISSION
Director's Dealing
2019-10-09 English
FORM 3/A SUBMISSION
Director's Dealing
2019-10-09 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.